Source comparison
PT-141 Not Working: Peptide Comparison
PT-141 (Bremelanotide) Melanocortin receptor agonist MC3R, MC4R 30–60 minutes High with daily use. Receptor internalization occurs after 5–7 days continuous dosing Best for cyclical protocols (twice weekly max); requires strict storage discipline and circadian
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- Melanocortin receptor agonist
- MC3R, MC4R
- 30–60 minutes
- High with daily use. Receptor internalization occurs after 5–7 days continuous dosing
- Best for cyclical protocols (twice weekly max); requires strict storage discipline and circadian timing
- Melanotan II
- Non-selective melanocortin agonist
- MC1R, MC3R, MC4R, MC5R
- 45–90 minutes
- Moderate. Broader receptor distribution reduces single-receptor saturation
- Longer half-life extends duration but increases tanning and appetite suppression side effects
- Kisspeptin-10
- Hypothalamic GnRH pulse generator
- KISS1R (GPR54)
- 60–120 minutes
- Low. Endogenous pulsatile system less prone to desensitization
- Upstream hormonal modulation; slower onset but doesn't rely on melanocortin system
- Oxytocin (intranasal)
- Central oxytocin receptor activation
- OXTR
- 15–30 minutes
- Very low. Receptor system designed for pulsatile activation
- Fastest onset but variable absorption; works through bonding/arousal pathways independent of melanocortin receptors
- PT-141's selective MC4R targeting makes it highly effective but also vulnerable to receptor downregulation. Melanotan II activates a broader receptor array, which reduces single-receptor fatigue but adds unwanted melanogenesis (tanning) and nausea. Kisspeptin works upstream of the melanocortin system entirely. It stimulates GnRH release, which cascades into downstream arousal signaling without direct receptor agonism. Each has trade-offs; PT-141 remains the gold standard when dosed cyclically.